Treatment of theophylline toxicity with oral activated charcoal. 1985

C N Sessler, and F L Glauser, and K R Cooper

We treated 14 patients who had an initial serum theophylline concentration greater than 30 micrograms/ml (48.3 +/- 19.4 micrograms/ml) and symptoms of theophylline toxicity with oral activated charcoal (OAC). Thirty-gram doses of OAC were administered approximately every two hours for two to four doses. Ten patients tolerated OAC and demonstrated a reduction in theophylline half-life to 5.6 +/- 2.5 hours with resolution of symptoms. Three of these ten patients were treated in the emergency department and discharged, making hospitalization unnecessary. The four patients with the highest initial theophylline concentrations (76.6 +/- 17.7 micrograms/ml) vomited all doses of OAC. Three of these four patients were treated with charcoal hemoperfusion with a reduction in the half-life to 5.2 +/- 1.0 hours. These data support the use of OAC as the primary therapeutic modality in the management of patients with theophylline toxicity. Patients with very high theophylline concentrations (greater than 50 micrograms/ml), however, usually vomit the OAC and may require charcoal hemoperfusion.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002606 Charcoal An amorphous form of carbon prepared from the incomplete combustion of animal or vegetable matter, e.g., wood. The activated form of charcoal is used in the treatment of poisoning. (Grant & Hackh's Chemical Dictionary, 5th ed) Activated Charcoal,Actidose,Actidose-Aqua,Adsorba,Carbomix,Charbon,CharcoAid,CharcoCaps,Charcodote,Formocarbine,Insta-Char,Kohle-Compretten,Kohle-Hevert,Kohle-Pulvis,Kohle-Tabletten Boxo-Pharm,Liqui-Char,Norit,Ultracarbon,Charcoal, Activated
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

C N Sessler, and F L Glauser, and K R Cooper
February 1984, Critical care medicine,
C N Sessler, and F L Glauser, and K R Cooper
January 1991, Intensive care medicine,
C N Sessler, and F L Glauser, and K R Cooper
January 1985, The Journal of family practice,
C N Sessler, and F L Glauser, and K R Cooper
December 1988, Singapore medical journal,
C N Sessler, and F L Glauser, and K R Cooper
March 1984, Clinical pharmacology and therapeutics,
C N Sessler, and F L Glauser, and K R Cooper
March 1990, Archives of internal medicine,
C N Sessler, and F L Glauser, and K R Cooper
September 1986, Annals of internal medicine,
C N Sessler, and F L Glauser, and K R Cooper
November 1987, The American journal of emergency medicine,
C N Sessler, and F L Glauser, and K R Cooper
July 1987, The Journal of pediatrics,
C N Sessler, and F L Glauser, and K R Cooper
March 1983, Clinical pharmacology and therapeutics,
Copied contents to your clipboard!